ANL 16.15 Increased By ▲ 0.66 (4.26%)
ASC 13.92 Decreased By ▼ -0.08 (-0.57%)
ASL 18.77 Decreased By ▼ -1.23 (-6.15%)
BOP 8.75 Increased By ▲ 0.05 (0.57%)
BYCO 7.54 Increased By ▲ 0.24 (3.29%)
FCCL 17.79 Increased By ▲ 0.81 (4.77%)
FFBL 23.08 Increased By ▲ 0.28 (1.23%)
FFL 15.25 Increased By ▲ 0.35 (2.35%)
FNEL 7.25 Increased By ▲ 0.19 (2.69%)
GGGL 16.90 Increased By ▲ 0.60 (3.68%)
GGL 29.20 Increased By ▲ 0.80 (2.82%)
HUMNL 6.48 Increased By ▲ 0.34 (5.54%)
JSCL 20.10 Decreased By ▼ -0.30 (-1.47%)
KAPCO 28.15 Decreased By ▼ -0.35 (-1.23%)
KEL 3.43 Increased By ▲ 0.02 (0.59%)
MDTL 2.24 Increased By ▲ 0.09 (4.19%)
MLCF 35.12 Increased By ▲ 2.64 (8.13%)
NETSOL 108.95 Increased By ▲ 7.50 (7.39%)
PACE 4.35 Increased By ▲ 0.15 (3.57%)
PAEL 28.00 Increased By ▲ 1.49 (5.62%)
PIBTL 8.42 Increased By ▲ 0.02 (0.24%)
POWER 7.00 Increased By ▲ 0.29 (4.32%)
PRL 16.65 Increased By ▲ 0.27 (1.65%)
PTC 9.17 Increased By ▲ 0.06 (0.66%)
SILK 1.48 Increased By ▲ 0.06 (4.23%)
SNGP 41.02 Decreased By ▼ -1.48 (-3.48%)
TELE 16.73 Increased By ▲ 0.28 (1.7%)
TRG 134.10 Increased By ▲ 5.75 (4.48%)
UNITY 29.85 Increased By ▲ 1.16 (4.04%)
WTL 2.54 Increased By ▲ 0.26 (11.4%)
BR100 4,716 Increased By ▲ 108.86 (2.36%)
BR30 20,840 Increased By ▲ 565.69 (2.79%)
KSE100 45,499 Increased By ▲ 870.01 (1.95%)
KSE30 17,825 Increased By ▲ 368.99 (2.11%)

Coronavirus
LOW Source: covid.gov.pk
Pakistan Deaths
28,328
1624hr
Pakistan Cases
1,266,826
62224hr
1.4% positivity
Sindh
466,750
Punjab
438,433
Balochistan
33,149
Islamabad
106,571
KPK
177,132
World

China approves AstraZeneca's lung cancer drug

  • The drugmaker is also seeking to catch up with Swiss rival Roche, whose Tecentriq is approved in China and many other countries for extensive-stage SCLC
19 Jul 2021

China has approved AstraZeneca drug, Imfinzi, to treat an aggressive type of lung cancer in adults, the group said on Monday, in a boost to its efforts to tackle the disease.

The drug's use with chemotherapy for adult patients with extensive-stage small cell lung cancer (SCLC) was approved by China's National Medical Products Administration, the Anglo-Swedish drugmaker said.

SCLC is an aggressive form of lung cancer that typically recurs and advances despite a response to chemotherapy. Only about 3% of those with extensive-stage disease live beyond five years after diagnosis.

China's approval came after positive results from a late-stage trial, which showed that the drug, when used with chemotherapy, helped improve patients' overall survival compared to chemotherapy alone. Results from a local trial also aligned with global results, AstraZeneca said.

Germany to give different second jab to AstraZeneca recipients under 60

The drugmaker is also seeking to catch up with Swiss rival Roche, whose Tecentriq is approved in China and many other countries for extensive-stage SCLC.

AstraZeneca's lung cancer portfolio includes a range of medicines including Imfinzi, which was approved in the United States and the European Union last year for extensive-stage SCLC.

Imfinzi, which enables the immune system to detect and attack certain cancer cells, is already approved in many countries as a treatment for the more common non-small cell lung cancer.

Lung cancer accounts for roughly a fifth of all deaths from cancer and is the leading cause of cancer deaths among both men and women.

Comments

Comments are closed.